Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Case Report
The Antimicrobial Therapy of the Future: Combating Resistances
| Beatriz Suay-García and María Teresa Pérez-Gracia* | ||
| Instituto Ciencias Biomédicas, Universidad CEU Cardenal Herrera, Moncada, Valencia, Spain | ||
| Corresponding Author : | María Teresa Pérez-Gracia Area Microbiología. Departamento Farmacia Instituto Ciencias Biomédicas Universidad CEU Cardenal Herrera Moncada, Valencia, Spain Tel: +34-00-96139 5272 Fax: +34-00-96 136 9000 E-mail: teresa@uch.ceu.es |
|
| Received April 25, 2014; Accepted May 29, 2014; Published June 06, 2014 | ||
| Citation: Suay-García B, Pérez-Gracia MT (2014) The Antimicrobial Therapy of the Future: Combating Resistances. J Infect Dis Ther 2:146. doi:10.4172/2332-0877.1000146 | ||
| Copyright: © 2014 Pérez-Gracia MT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
Related article at Pubmed Scholar Google |
||
Abstract
The appearance of antibiotic resistance is an increasing problem in our society, where the adaptation of microorganisms to conventional therapies has been favored due to their incorrect use. This has driven the scientific community to develop new therapeutic alternatives hoping to obtain treatments that are more effective against increasingly resistant bacteria. The purpose of this study is to review the existent knowledge on the therapeutic alternatives that are being developed to treat cases of infection with antibiotic resistant bacteria. To do so, scientific publications were consulted on the MEDLINE database using different search terms. The bibliography consulted indicates that a great variety of therapeutic alternatives are currently being developed among which the most relevant are probiotics, synthetic peptides, bacteriophages and nanoparticles. Some of these measures, such as probiotics, are already being introduced in some hospitals with positive results. Others, such as synthetic peptides, bacteriophages or nanoparticles are still in the early stages of development and clinical trials. Moreover, there is a clear tendency to go back to the more classical medicine turning to plant extracts and essential oils whose active ingredients have been proven to have therapeutic activity. This shift towards less conventional therapies is marking the beginning of a post-antibacterial era in which antibiotics will most probably be replaced for probiotics, bacteriophages, synthetic peptides or even inorganic nanoparticles.
